Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is frequently misdiagnosed as other neurologic conditions. When there is a misdiagnosis, it can have a significant impact on the lives of patients and their caregivers. Recently, new guidelines have been published to help clinicians identify symptoms early and guide selection of the best medications for patients with CIDP. Equally important to patients and their caregivers, the guidelines encourage them to become more involved in the management of CIDP.
In addition, emerging agents and new immunoglobulin formulations are under investigation through clinical trials and may help optimize care for patients who do not easily tolerate other formulations. Overall, it is important that patients and caregivers get on the same page with the care team to select a treatment specific to their symptoms and healthcare needs. Please join us for “You Have CIDP…Now What?” a 1-hour long presentation on Thursday, January 12 at 2:00 PM ET.
The patient-focused panel of CIDP experts and patients will discuss the details of CIDP symptoms, guideline-recommended tests to confirm diagnoses, best practices to select treatment, and strategies to effectively communicate with doctors about your care. Click here to register.